Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Horizon Discovery Wins Drug Screening Contract | Contract Pharma

What are you searching for?

Sign in
Breaking News

Horizon Discovery Wins Drug Screening Contract

Will perform drug combination screening on lead oncology asset

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Horizon Discovery Group’s CombinatoRx division has entered an agreement with a top ten pharma company to profile a lead oncology asset. Horizon CombinatoRx will receive approximately $450,000 for work to be completed within a six-month period.   
 
Horizon will support proof-of-concept, monotherapy screening, and combination screening for the lead asset, providing access to its cHTS platform and Chalice analytics software, which enable the screening and analysis of thousands of complementary drug combinations. Horizon Discovery recently completed the acquisition of the CombinatoRx service business and assets from Zalicus Inc.
 
Dr. Darrin Disley, chief executive officer of Horizon Discovery Group, said, “We are delighted that Horizon CombinatoRx continues to gain traction in the market, following the acquisition earlier this year.  This latest contract with a top ten pharma in the oncology space continues to demonstrate the potential of this business and the value Horizon CombinatoRx can offer to support key drug discovery and development programs in cancer.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics